secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K/A
Filed at:   2022-04-14T23:59:59+00:00
Accession:  0001564590-22-014489
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants orphan drug designation to aTyr Pharma's efzofitimod for systemic sclerosis
--------------------------------------------------------------------------------

- FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.
- Orphan designation may provide 7-year market exclusivity, tax credits, and waiver of FDA fees.
- Efzofitimod is aTyr's lead therapeutic candidate; this designation supports its development program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022014489/0001564590-22-014489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022014489/life-8ka_20220412.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-014489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer